Skip to content
approvedImmune & Inflammation

Romiplostim

Also known as: Nplate, AMG 531, TPO-mimetic peptibody

Romiplostim (Nplate) is an Fc-peptide fusion protein (peptibody) that mimics thrombopoietin (TPO) to stimulate platelet production. FDA-approved in 2008 for chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy, it was the first TPO receptor agonist approved for clinical use. Romiplostim contains four TPO-mimetic peptides fused to an IgG1 Fc domain, providing a targeted approach to raising platelet counts without the autoimmune risks of recombinant TPO.

3 cited references·6 researched benefits

Quick Answer

Romiplostim (Nplate) is an Fc-peptide fusion protein that activates the thrombopoietin (TPO) receptor to stimulate platelet production in bone marrow. FDA-approved in 2008 for chronic immune thrombocytopenia (ITP), it is administered as a once-weekly subcutaneous injection with doses adjusted to maintain platelet counts above 50,000/μL. It achieves durable platelet response in 79–88% of ITP patients and avoids the immunogenicity risks associated with recombinant TPO proteins.

Key Facts

Mechanism
Romiplostim is a peptibody consisting of two identical subunits, each containing an IgG1 Fc domain fused to two 14-amino acid TPO-mimetic peptides (four peptide domains total). These peptides bind to the extracellular domain of the thrombopoietin receptor (c-Mpl/MPL) on megakaryocyte progenitors and mature megakaryocytes in bone marrow, activating the JAK2-STAT5 and MAPK signaling cascades. This stimulates megakaryocyte proliferation, differentiation, and maturation, increasing platelet production over 5–10 days. Because the mimetic peptides have no sequence homology to endogenous TPO, romiplostim does not induce cross-reactive anti-TPO antibodies. The Fc domain extends half-life through FcRn-mediated recycling.
Research Status
approved
Half-Life
~3.5 days (median 1–34 days, dose-dependent)
Molecular Formula
C₂₆₄₂H₄₀₄₄N₇₁₂O₇₉₈S₁₈ (approximate, peptibody)
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Durable platelet response in 79–88% of ITP patients — significantly reduces bleeding riskstrong
  • Reduces need for rescue medications (corticosteroids, IVIG, platelet transfusions)strong
  • Well-tolerated with once-weekly subcutaneous dosing — allows home self-injection after trainingstrong
  • Effective in both splenectomized and non-splenectomized ITP patientsstrong
  • Long-term efficacy sustained over 5+ years in extension studies without tachyphylaxismoderate
  • Being investigated for other thrombocytopenias including chemotherapy-induced and aplastic anemiapreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection1 mcg/kg initial, adjusted by 1 mcg/kg increments (max 10 mcg/kg)Once weeklyTitrate to achieve and maintain platelet count ≥50,000/μL. Adjust dose by 1 mcg/kg weekly based on platelet response. If platelet count >200,000/μL, reduce dose. If >400,000/μL, hold dose. Monitor CBC weekly until stable, then monthly.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Headache — most common adverse event, occurring in 10–15% of patientscommon
  • Arthralgia, myalgia, and fatiguecommon
  • Upper respiratory tract infections and dizzinesscommon
  • Bone marrow reticulin fibrosis — increased reticulin observed in some patients on long-term therapy, generally reversible upon discontinuationserious
  • Thromboembolic events — risk of arterial and venous thrombosis when platelet counts exceed target rangeserious
  • Rebound thrombocytopenia — platelet counts may drop below baseline after discontinuation, requiring monitoringserious

Frequently Asked Questions

What is a peptibody and how is romiplostim different from regular peptides?
A peptibody is a fusion protein combining bioactive peptide sequences with an antibody Fc domain. Romiplostim has four short TPO-mimetic peptides (14 amino acids each) fused to an IgG1 Fc backbone. The Fc domain extends the half-life from minutes to days through FcRn recycling and provides structural stability. This makes romiplostim much larger (~60 kDa) than typical therapeutic peptides and gives it antibody-like pharmacokinetics. The term "peptibody" was coined by Amgen, which developed this technology platform.
Can romiplostim cure ITP or does it only treat symptoms?
Romiplostim primarily treats symptoms by stimulating platelet production to compensate for the accelerated platelet destruction that defines ITP. It does not address the underlying autoimmune cause. However, some long-term data suggest that a subset of patients (10–30%) can achieve sustained platelet responses after discontinuing romiplostim, possibly due to immune modulation during treatment. This potential for treatment-free remission is an active area of research, but most patients require ongoing therapy.
Is bone marrow fibrosis from romiplostim dangerous?
Bone marrow reticulin fibrosis has been observed in some patients receiving long-term romiplostim therapy. Current evidence suggests this is generally mild (grade 1–2), does not progress to collagen fibrosis or myelofibrosis in most cases, and is reversible upon drug discontinuation. Monitoring guidelines recommend periodic peripheral blood smear review for signs of fibrosis (teardrop cells, nucleated red blood cells). If significant fibrosis is suspected, bone marrow biopsy should be performed and romiplostim may need to be discontinued.
How does romiplostim compare to eltrombopag?
Both are TPO receptor agonists for ITP but differ in structure and administration. Romiplostim is a peptibody given as a weekly subcutaneous injection with dose adjustment by a healthcare provider. Eltrombopag (Promacta) is a small-molecule oral tablet taken daily, offering the convenience of oral dosing. Efficacy is broadly similar, with both achieving platelet responses in 70–80% of patients. Eltrombopag has dietary restrictions (no dairy or calcium within 4 hours) and potential hepatotoxicity requiring liver monitoring. Choice between them often depends on patient preference for injection vs oral dosing.

References

  1. 1
    Romiplostim in thrombocytopenic patients with chronic immune thrombocytopenic purpura(2008)PubMed ↗
  2. 2
    Long-term safety and efficacy of romiplostim in patients with chronic immune thrombocytopenia(2010)PubMed ↗
  3. 3
    Thrombopoietin receptor agonists in immune thrombocytopenia: a systematic review and meta-analysis(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19